Alternative Medicine Company Investment Opportunity in New Delhi, India

- Business is revolutionizing the management of chronic and neuropathic pain in India with a focus on safety and efficacy.

- Our licensed healthcare company is pioneering the country's first range of GMP-compliant, lab-certified, ayurvedic cannabinoid formulations designed to provide patients with a natural alternative to traditional pain medications.

- First mover advantage: First to bring cannabinoid based pain management solutions into mainstream healthcare and retail in India.

- Onco Range: Launched India's first and only Onco-focused range of CBD formulations addressing big problem areas in cancer care.

- Endorsement from the medical community: Extensive inroads into the medical community with KOL's prescribing and endorsing our medications.

- Backed by clinical trials: 1st Indian company to conduct clinical trials and bring CBD-based pain management products into mainstream healthcare and retail.

- Extensive distribution: Access to extensive distribution through partnerships with the largest healthcare and big box companies such as Apollo, Guardian, Genisan Healthcare, Max Group, Spencer’s Retail, and Nature Basket.

- Traction: Since last year, 9X growth in Offline sales and 3X growth in sales.

- Marquee investors onboarded from Apollo Hospital, Panthera Peak Ventures, IIFL Finance,  Mahindra First.

- The business has all the required licenses and certifications.

Business is revolutionizing the management of chronic and neuropathic pain in India with a focus on safety and efficacy. Our licensed healthcare company is pioneering the country's first range of GMP-compliant, lab-certified, ayurvedic cannabinoid formulations designed to provide patients with a natural alternative to traditional pain medications.

It will be answered after the introduction.

It will be answered after the introduction.

Pre Seed - Equity round, INR 45L @ INR 3.7Cr.

Seed - INR 1.5 Cr, CCD.

Ownership.

Founder - 86.4%

Investors - 13.6%